Birdwatch Note
2024-11-04 14:39:19 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
インド政府は抗フィラリア薬としてイベルメクチンを国家必須医薬品に登録したので、生産を止めることは出来ません なおインド政府はイベルメクチンの新型コロナウイルス感染症治療への使用を禁止しています https://pib.gov.in/PressReleasePage.aspx?PRID=1858931 https://t.co/ycZd8z7UlB
Written by BFFA3FF9DA5EBAF072AE80CC9C7256B14822D1F0AFF08E9F2E49E3EBA95A4284
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1853339629883388067
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1853446936965366229
- noteId - 1853446936965366229
- participantId -
- noteAuthorParticipantId - BFFA3FF9DA5EBAF072AE80CC9C7256B14822D1F0AFF08E9F2E49E3EBA95A4284 Participant Details
- createdAtMillis - 1730731159808
- tweetId - 1853339629883388067
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- インド政府は抗フィラリア薬としてイベルメクチンを国家必須医薬品に登録したので、生産を止めることは出来ません なおインド政府はイベルメクチンの新型コロナウイルス感染症治療への使用を禁止しています https://pib.gov.in/PressReleasePage.aspx?PRID=1858931 https://t.co/ycZd8z7UlB
Note Ratings
| rated at | rated by | |
| 2024-11-04 16:40:09 -0600 | Rating Details | |
| 2024-11-04 15:36:49 -0600 | Rating Details | |
| 2024-11-04 15:17:33 -0600 | Rating Details | |
| 2024-11-04 14:48:03 -0600 | Rating Details | |
| 2024-11-04 14:43:02 -0600 | Rating Details | |
| 2024-11-04 14:31:40 -0600 | Rating Details | |
| 2024-11-04 14:18:51 -0600 | Rating Details | |
| 2024-11-04 13:55:51 -0600 | Rating Details | |
| 2024-11-04 13:14:00 -0600 | Rating Details | |
| 2024-11-04 10:51:29 -0600 | Rating Details | |
| 2024-11-04 10:46:09 -0600 | Rating Details | |
| 2024-11-04 09:30:39 -0600 | Rating Details | |
| 2024-11-04 09:14:23 -0600 | Rating Details | |
| 2024-11-04 09:09:31 -0600 | Rating Details | |
| 2024-11-04 09:05:51 -0600 | Rating Details | |
| 2024-11-04 09:03:10 -0600 | Rating Details | |
| 2024-11-06 15:17:38 -0600 | Rating Details | |
| 2024-11-06 11:24:46 -0600 | Rating Details | |
| 2024-11-05 22:22:06 -0600 | Rating Details | |
| 2024-11-05 03:17:42 -0600 | Rating Details | |
| 2024-11-05 00:19:56 -0600 | Rating Details | |
| 2024-11-04 21:53:53 -0600 | Rating Details | |
| 2024-11-04 19:39:13 -0600 | Rating Details | |
| 2024-11-04 18:22:38 -0600 | Rating Details | |
| 2024-11-04 17:03:52 -0600 | Rating Details | |
| 2024-11-04 15:08:18 -0600 | Rating Details | |
| 2024-11-04 13:23:08 -0600 | Rating Details | |
| 2024-11-04 12:54:40 -0600 | Rating Details | |
| 2024-11-04 11:16:15 -0600 | Rating Details | |
| 2024-11-04 10:14:06 -0600 | Rating Details | |
| 2024-11-04 09:43:06 -0600 | Rating Details | |
| 2024-11-04 09:27:19 -0600 | Rating Details | |
| 2024-11-04 08:59:06 -0600 | Rating Details | |
| 2024-11-04 08:55:07 -0600 | Rating Details | |
| 2024-11-06 00:28:51 -0600 | Rating Details | |
| 2024-11-05 02:20:48 -0600 | Rating Details | |
| 2024-11-04 21:54:28 -0600 | Rating Details | |
| 2024-11-04 21:45:32 -0600 | Rating Details | |
| 2024-11-04 19:45:28 -0600 | Rating Details | |
| 2024-11-04 18:19:43 -0600 | Rating Details | |
| 2024-11-04 15:54:03 -0600 | Rating Details | |
| 2024-11-04 15:00:41 -0600 | Rating Details | |
| 2024-11-04 15:00:27 -0600 | Rating Details | |
| 2024-11-04 13:42:22 -0600 | Rating Details | |
| 2024-11-04 13:33:17 -0600 | Rating Details | |
| 2024-11-04 11:42:40 -0600 | Rating Details | |
| 2024-11-04 11:07:08 -0600 | Rating Details | |
| 2024-11-04 10:10:34 -0600 | Rating Details | |
| 2024-11-04 09:37:07 -0600 | Rating Details | |
| 2024-11-04 09:36:06 -0600 | Rating Details | |
| 2024-11-04 09:18:45 -0600 | Rating Details | |
| 2024-11-04 09:10:29 -0600 | Rating Details | |
| 2024-11-04 09:04:43 -0600 | Rating Details | |
| 2024-11-04 09:01:21 -0600 | Rating Details | |
| 2024-11-07 05:27:47 -0600 | Rating Details | |
| 2024-11-04 20:33:27 -0600 | Rating Details | |
| 2024-11-04 20:07:03 -0600 | Rating Details | |
| 2024-11-04 19:57:06 -0600 | Rating Details | |
| 2024-11-04 19:04:31 -0600 | Rating Details | |
| 2024-11-04 16:04:04 -0600 | Rating Details | |
| 2024-11-04 15:53:54 -0600 | Rating Details | |
| 2024-11-04 15:53:16 -0600 | Rating Details | |
| 2024-11-04 14:57:38 -0600 | Rating Details | |
| 2024-11-04 11:10:00 -0600 | Rating Details | |
| 2024-11-04 09:44:40 -0600 | Rating Details | |
| 2024-11-04 09:35:12 -0600 | Rating Details |